Antiretroviral Therapy

Patients with HIV on long-acting cabotegravir plus rilpivirine reported improved treatment satisfaction compared with daily ART at 96 weeks, according to results from the phase 3 FLAIR study.

Physicians should discuss risks associated with certain antiretroviral agents, such as dolutegravir, and contraception with women with HIV who are of childbearing age, researchers reported IDWeek.

Integrase strand transfer inhibitors are associated with an increased risk for weight gain and hyperglycemia or diabetes, according to data presented at IDWeek.

Dec. 1 marks the 32nd annual World AIDS Day, which was started to support people living with HIV/AIDS and to commemorate those who have died from the disease.

Despite guidelines recommending periodic laboratory testing in patients with HIV on ART, it may be beneficial to delay liver, renal and lipid testing in low-risk patients to minimize exposure to COVID-19, new data suggest.

Study results presented at IDWeek demonstrated that the pandemic did not cause HIV treatment interruptions during the numerous global trials assessing long-acting cabotegravir and rilpivirine for ART.

A majority of virologically suppressed patients with HIV considered long-acting injectable ART to be acceptable, according to results from the CUSTOMIZE study presented during IDWeek.

Switching to bictegravir/emtricitabine/tenofovir was safe and effective, resulting in sustained viral suppression among people living with HIV, according research presented at the HIV Glasgow virtual meeting.

The prevalence of Alzheimer’s disease is elevated among patients with HIV, and the prevalence of early onset Alzheimer’s disease is even higher among patients who are not being treated with ART, study findings showed.

A brief intervention that included cognitive behavioral and motivational enhancement therapy improved alcohol abstinence and viral suppression among Vietnamese patients with HIV through 52 weeks, according to a study in JAMA Network Open.